Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8748920 | 1.00 | CNR1 (0.49) | CNR1DAGLALMNAGAANAAA | |
| SCHEMBL10353701 | 1.00 | CNR1 (0.49) | CNR1DAGLALMNAGAANAAA | |
| SCHEMBL3326274 | 1.00 | CNR1 (0.49) | CNR1DAGLALMNAGAANAAA | |
| SCHEMBL1978843 | 1.00 | CNR1 (0.49) | CNR1DAGLALMNAGAANAAA | |
| SCHEMBL1978841 | 1.00 | CNR1 (0.49) | CNR1DAGLALMNAGAANAAA | |
| SCHEMBL7715586 | 1.00 | CNR1 (0.49) | CNR1DAGLALMNAGAANAAA | |
| SCHEMBL9511157 | 1.00 | CNR1 (0.49) | CNR1DAGLALMNAGAANAAA | |
| SCHEMBL10353311 | 1.00 | CNR1 (0.49) | CNR1DAGLALMNAGAANAAA | |
| SCHEMBL3326271 | 1.00 | CNR1 (0.49) | CNR1DAGLALMNAGAANAAA | |
| SCHEMBL8748932 | 1.00 | CNR1 (0.49) | CNR1DAGLALMNAGAANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 422 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114404424-A | A pharmaceutical composition for treating alopecia, and its preparation method | 硬核医药科技(上海)有限公司 | 2022-04-29 | — | — | CN | claimed |
| US-20190209472-A1 | FORMULATIONS FOR DERMAL DELIVERY OF POLYMER CONJUGATES OF INDOLOCARBAZOLE COMPOUNDS WITH REDUCED EXPOSURE | SIENNA BIOPHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | claimed |
| US-10342765-B2 | Therapeutic compositions comprising monoterpenes | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2019-07-09 | — | — | US | claimed |
| WO-2019112964-A1 | FORMULATIONS FOR DERMAL DELIVERY OF POLYMER CONJUGATES OF INDOLOCARBAZOLE COMPOUNDS WITH REDUCED EXPOSURE | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | claimed |
| US-20180147156-A1 | Therapeutic Compositions Comprising Monoterpenes | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2018-05-31 | — | — | US | claimed |
| US-20160220509-A1 | THERAPEUTIC COMPOSITIONS COMPRISING MONOTERPENES | UNIVERSITY OF SOUTHERN CALIFORNIA | 2016-08-04 | — | — | US | claimed |
| US-7323191-B2 | Transdermal warfarin system | ALZA CORPORATION (US) | 2008-01-29 | — | — | US | claimed |
| EP-1651197-A1 | TRANSDERMAL WARFARIN-CONTAINING DELIVERY SYSTEM | ALZA Corporation (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1216036-B1 | TRANSDERMAL ADMINISTRATION OF N-(2,5-DISUBSTITUTED PHENYL)-N'-(3-SUBSTITUTED PHENYL)-N'-METHYL GUANIDINES | ALZA CORP (US) | 2005-11-16 | — | — | EP | claimed |
| EP-1169025-B1 | TRANSDERMAL DRUG DELIVERY DEVICES COMPRISING A POLYURETHANE DRUG RESERVOIR | ALZA CORP (US) | 2005-08-24 | — | — | EP | claimed |
| US-5753245-A | COMPRISING WATER INSOLUBLE MICRONIZED POLYMER PARTICLES, SURFACTANT, EMOLLIENT, WATER; NONABRASIVE | THE PROCTER & GAMBLE COMPANY (US) | 1998-05-19 | — | — | US | claimed |
| US-5720961-A | MIXTURE OF INSOLUBLE MICRONIZED CLEANING PARTICLES, SURFACTANTS, LOTION AND WATER | THE PROCTER & GAMBLE COMPANY (US) | 1998-02-24 | — | — | US | claimed |
| CN-1159159-A | Personal cleansing compositions | PROCTER & GAMBLE (US) | 1997-09-10 | — | — | CN | claimed |
| CN-1159160-A | Thickened nonbarasive personal cleansing compositions | PROCTER & GAMBLE (US) | 1997-09-10 | — | — | CN | claimed |
| EP-0777465-A1 | THICKENED NONABRASIVE PERSONAL CLEANSING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1997-06-11 | — | — | EP | claimed |
| EP-0777464-A1 | PERSONAL CLEANSING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1997-06-11 | — | — | EP | claimed |
| US-5635469-A | MANUAL LIQUID CLEANSER DISPENSER HAVING FOAM-PRODUCING NOZZLE; NON-AEROSOL | THE PROCTER & GAMBLE COMPANY (US) | 1997-06-03 | — | — | US | claimed |
| US-5534265-A | INSOLUBILE POLYMER PARTICLES, GELLING AGENT, SURFACTANT, EMOLIENT | THE PROCTER & GAMBLE COMPANY (US) | 1996-07-09 | — | — | US | claimed |
| WO-1996006596-A1 | THICKENED NONABRASIVE PERSONAL CLEANSING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1996-03-07 | — | — | WO | claimed |
| WO-1996006595-A1 | PERSONAL CLEANSING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1996-03-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209472-A1 | FORMULATIONS FOR DERMAL DELIVERY OF POLYMER CONJUGATES OF INDOLOCARBAZOLE COMPOUNDS WITH REDUCED EXPOSURE | YAP1, S100A10, KRT18 | CNR1 375/4885DAGLA 3159/4885LMNA 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.